Stocks · News reference
EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results from LUGANO,
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzingaRBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
Read original at benzingaChardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
Read original at benzinga